Society for Translational Oncology navigateright Episode
Oladapo Yeku, MD, PhD
Massachusetts General Hospital
Video Overview: https://youtu.be/_X68mu3JHUY
Solid tumor malignancies have yet to benefit from chimeric antigen receptor (CAR) T-cell therapy compared with hematologic malignancies, such as B-cell acute lymphoblastic leukemia and multiple myeloma. Despite initially promising preclinical data, early clinical trials in ovarian cancer have not yielded meaningful results. It is now accepted that the solid tumor microenvironment, which includes immunosuppressive immune cells, stromal cells, and cytokines, contributes to active determent of effective T-cell activity. We sought to develop strategies to improve CAR T-cell potency and overcome the hostile tumor microenvironment in ovarian cancer.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.